30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Seikagaku Grows in Low Double-Digits on Favorable U.S. Reimbursement Stauts -

Seikagaku reported FY 2Q19 revenue of JPY ¥7,906MM (USD $71.4MM), +12.5% vs. 2Q18.

  • U.S. viscosupplement sales had sizeable volume increases due to qualification for preferential reimbursement status with multiple insurance carriers and well as conversion of competitive accounts
  • Sales of five injection treatment SUPARTZ FX saw volume declines due to U.S. trending toward favoring single treatment products
  • Sales volume grew in China but was offset by currency headwinds
  • ORTHOWORLD projects Seikagaku full calendar year 2019 revenue of $275.6MM, +7.7% vs. 2018


ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).

  2Q19 2Q18 $ Chg % Chg
Orthobiologics $71.4 $63.5 $7.9 12.5%
  1H19 1H18 $ Chg % Chg
Orthobiologics $140.4 $128.7 $11.7 9.1%


Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.